- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03005639
ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma
Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma
• To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma after 8 weeks of neoadjuvant vemurafenib and cobimetinib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Vemurafenib and cobimetinib are FDA-approved drugs to treat advanced melanoma that has a mutated (changed) form of a cell protein called BRAF (BRAF V600 mutation). The purpose of this study is to determine if vemurafenib and cobimetinib can be safely given to patients with this type of melanoma to shrink it before surgery. This research is being done because patients with melanoma spread to lymph node have high chance of melanoma recurrence even after lymph node removal surgery, and currently there is no approved medicine to use for patients with BRAF V600 mutant melanoma before lymph node removal surgery.
Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
Before the participant begins the study:
The participant will need to have the following exams, tests or procedures to find out if eligibility is met.
- A skin exam
- An eye exam
- An electrocardiogram (ECG) which is a test that tracks the electricity of the heart
- An echocardiogram (a test that uses sound waves to create pictures of the heart) or MUGA scan (a test that uses radioactive materials called tracers to show the heart chambers) which is a test to evaluate the function of the heart
- A blood test
- A biopsy of lymph node
If the exams and tests listed above show that the individual can take part in the study, and he or she chooses to take part, then the participant will take the study drugs for 8weeks. He/she will take vemurafenib 240mg 4tablets twice daily for 56days and cobimetinib 20mg 3 tablets daily on days 1-21 and 29-49. While taking these pills, the following extra exams and tests will be needed.
- Four extra blood samples will be drawn. One blood sample will be drawn immediately before the first dose of the vemurafenib and trametinib pills. Then blood sample will be drawn 2 weeks, 4weeks, and 8weeks after starting the pills.
- A biopsy of lymph node will be performed 2weeks after starting the pills.
- Skin exams will be performed immediately before the first dose, 2weeks, 4weeks, and 8weeks after starting the pills.
- Eye exams will be performed 4weeks, 8weeks after starting the pills.
- An ECG will be performed 2weeks, 4weeks, and 8weeks after starting the pills.
- An echocardiogram or MUGA scan will be performed 4weeks after starting the pills.
- A CT scan will be performed 8weeks after starting the pills.
Once the participant finishes 8weeks of study drugs, he or she will undergo surgery within a week. After surgery, the individual will need the following extra exam.
• A skin exam A blood sample will be taken for the study at the first study visit, two week visit and eight week visit. Tissue from a core biopsy will be taken for the study at the first study visit and two week visit. This sample is required in order for the individual to take part in this study because the research on the sample is an important part of the study. The research biopsy is done in a similar way to biopsies done for diagnosis. Neither the participant nor the participant's health care plan/insurance carrier will be billed for the collection of the blood and tissue sample that will be used for this study. The results will not be made available to the participant during participation in the trial.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Inova Schar Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients will be included in the study based on the following criteria:
- Signed informed consent
- Histologically confirmed, palpable, regional lymph node metastatic melanoma ≥ 1.5cm (stage IIIB-C; N1b-3) either at initial presentation or at regional lymph node recurrence considered surgically resectable at baseline by the treating medical oncologist and surgical oncologist
- Patients with intransit or satellite metastases with lymph node involvement are allowed if considered surgically resectable at baseline
- Measurable disease per RECIST 1.1
- Melanoma must be documented to contain a BRAFV600 mutation by a CLIA approved laboratory
- No evidence of distant metastasis
- Age ≥ 18 years
- ECOG performance status ≤1
Adequate bone marrow function as indicated by the following:
- ANC greater than 1500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin greater than 9 g/dL
- Adequate renal function, as indicated by creatinine ≤1.5 x the upper limit of normal (ULN)
- Adequate liver function, as indicated by bilirubin ≤1.5 x ULN
- AST or ALT less than 3 x ULN (patients with documented liver metastases: AST and/or ALT ≤5 x ULN)
- Able to swallow pills
- Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
- Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- Willing and able to undergo biopsy for research purposes
- Willing and able to sign informed consent
Exclusion Criteria:
- Had prior radiotherapy at lymph node basin
- Prior treatment with BRAF inhibitor or MEK inhibitor
- Active infection
- Pregnant, lactating or breast feeding women
- Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- History of malabsorption or other condition that would interfere with absorption of vemurafenib or cobimetinib
- Any underlying medical or psychiatric condition, which in the opinion of the Investigator will make the administration of vemurafenib and cobimetinib hazardous
- Unwillingness or inability to comply with study and follow-up procedures.
The following foods/supplements are prohibited at least 7 days prior to initiation of and during study treatment:
- St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)
- Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vemurafenib/Cobimetinib
Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma.
In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
|
All participants will receive study treatment for up to 56 days (8 weeks).
After completing treatment, they will undergo a lymph node removal surgery.
After surgery, they will have follow-up visit 2-4 weeks after surgery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiologic Complete Response Rate
Time Frame: Day 56 (+/- 3 days)
|
Radiologic complete response rate will be the primary endpoint.
This will be assessed after completion of the 8-week treatment of vemurafenib and cobimetinib by CT measurements of tumor diameter pre-treatment and at day 56 (± 3 days) using RECIST 1.1.
Complete response (CR) is defined by a reduction in the short-axis diameter of any pathologic lymph node to less than 10 mm, whereas partial response (PR) is defined as 30% or more decrease in the short axis.
The analysis of response rate is based on the efficacy evaluable patients who has post-treatment CT scan at Day 43.
Patients who discontinued study drug or withdraw from the study will be included only if they had post-treatment CT scan.
We will calculate radiologic complete response rate with 95% confidence interval.
|
Day 56 (+/- 3 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate, pathologic complete response rate
Time Frame: Day 56 (+/- 3 days)
|
Overall response rate is defined as the proportion of the patients in the analysis population who have a CR or PR.
Pathologic complete response is defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of all sampled lymph nodes +/- primary melanoma specimen following completion of neoadjuvant systemic therapy (ypT0ypN0 in the current AJCC staging system).
The analysis of pathologic response is based on the efficacy evaluable patients who underwent therapeutic lymph node dissection.
Patients who discontinued study drug or withdraw from the study will be included only if they underwent therapeutic lymph node dissection.
We will calculate the pathological complete response rate with 95% confidence interval.
|
Day 56 (+/- 3 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sekwon Jang, MD, Inova Schar Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-2316
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IIIB-C Melanoma
-
Philogen S.p.A.RecruitingMelanoma Stage IIIB/CSpain, United States, Switzerland
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaCompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal MelanomaUnited States
-
Yale UniversityNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
Clinical Trials on Vemurafenib and Cobimetinib
-
Center Eugene MarquisCompletedMalignant MelanomaFrance
-
Radboud University Medical CenterThe Netherlands Cancer Institute; IsalaRecruitingMelanoma, Malignant, of Soft PartsNetherlands
-
Grupo Español Multidisciplinar de MelanomaRoche Farma, S.A; Pivotal S.L.Completed
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Australia
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Fondazione Melanoma OnlusRoche S.p.aTerminatedMelanoma | Melanoma (Skin) | Melanoma StageItaly
-
Technische Universität DresdenTerminatedBrain Metastases | Malignant Melanoma Stage IV | BRAF V600 MutationGermany
-
Melissa Burgess, MDGenentech, Inc.TerminatedActive Melanoma Brain MetastasesUnited States
-
Hoffmann-La RocheWithdrawn
-
Cancer Research UKRoyal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of BirminghamRecruitingGlioma | Melanoma | Carcinoma, Non-Small-Cell Lung | Multiple Myeloma | Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Thyroid Cancer, Papillary | Thyroid Carcinoma, Anaplastic | Laryngeal Neoplasms | Erdheim-Chester Disease | Haematological MalignancyUnited Kingdom